148 related articles for article (PubMed ID: 17714563)
1. Acute cutaneous T-cell lymphoma transformation during treatment with alemtuzumab.
Faguer S; Launay F; Ysebaert L; Mailhol C; Estines-Chartier O; Lamant L; Paul C
Br J Dermatol; 2007 Oct; 157(4):841-2. PubMed ID: 17714563
[No Abstract] [Full Text] [Related]
2. Severe diarrhoea during Campath-1H treatment for refractory cutaneous T-cell lymphoma.
Goteri G; Rupoli S; Tassetti A; Pulini S; Morichetti D; Filosa A; Mandolesi A; Veccia S; Leoni P; Bearzi I
Ann Hematol; 2006 Sep; 85(9):617-9. PubMed ID: 16821018
[No Abstract] [Full Text] [Related]
3. The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution.
Thachil J; Jadhav V; Gautam M; McKew S; Arumainathan A; Collins D; Smyth C; Harper J; Pettitt A
Br J Haematol; 2007 Aug; 138(4):559-60. PubMed ID: 17587337
[No Abstract] [Full Text] [Related]
4. Alemtuzumab in Sézary syndrome: efficient but not innocent.
Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.
Thursky KA; Worth LJ; Seymour JF; Miles Prince H; Slavin MA
Br J Haematol; 2006 Jan; 132(1):3-12. PubMed ID: 16371014
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab in peripheral T-cell malignancies.
Dearden C
Cancer Biother Radiopharm; 2004 Aug; 19(4):391-8. PubMed ID: 15453953
[TBL] [Abstract][Full Text] [Related]
7. Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome.
Roch N; Salameire D; Gressin R; Morand P; Epaulard O; Pavese P; Brion JP; Stahl JP
Scand J Infect Dis; 2008; 40(4):343-6. PubMed ID: 17934981
[TBL] [Abstract][Full Text] [Related]
8. Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia.
Sohani AR; Ferry JA; Chang PS; Abramson JS
J Clin Oncol; 2010 Feb; 28(5):e69-72. PubMed ID: 19917859
[No Abstract] [Full Text] [Related]
9. Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab.
Crowley B; Woodcock B
Br J Haematol; 2002 Oct; 119(1):279-80. PubMed ID: 12358942
[No Abstract] [Full Text] [Related]
10. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.
Zinzani PL; Alinari L; Tani M; Fina M; Pileri S; Baccarani M
Haematologica; 2005 May; 90(5):702-3. PubMed ID: 15921394
[TBL] [Abstract][Full Text] [Related]
11. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab.
Ghobrial IM; Otteman LA; White WL
N Engl J Med; 2003 Dec; 349(26):2570-2; discussion 2570-2. PubMed ID: 14695424
[No Abstract] [Full Text] [Related]
12. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy.
Ingram PR; Howman R; Leahy MF; Dyer JR
Clin Infect Dis; 2007 Jun; 44(12):e115-7. PubMed ID: 17516390
[TBL] [Abstract][Full Text] [Related]
13. [Persistent influenza virus infection in a patient treated with alemtuzumab].
Burrel S; Dilhuydy S; Bouabdallah K; Lafon MÉ; Milpied N; Fleury H
Med Mal Infect; 2010 Nov; 40(11):657-9. PubMed ID: 20638206
[No Abstract] [Full Text] [Related]
14. Two cases of opportunistic parasite infections in patients receiving alemtuzumab.
Desoubeaux G; Caumont C; Passot C; Dartigeas C; Bailly E; Chandenier J; Duong TH
J Clin Pathol; 2012 Jan; 65(1):92-5. PubMed ID: 22052936
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab.
Ravandi F; O'Brien S
Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
Boyd K; Dearden CE
Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
[TBL] [Abstract][Full Text] [Related]
17. Treatment with alemtuzumab in a case of refractory primary cutaneous CD30-negative CD8-positive cytotoxic large T-cell lymphoma.
Gutierrez A; Rodriguez J; Ramos R; Gines J; Sampol A; Galmes B; Besalduch J
Eur J Haematol; 2004 May; 72(5):377-8. PubMed ID: 15059077
[No Abstract] [Full Text] [Related]
18. Taking the measure of alemtuzumab.
Gilleece MH
Leuk Res; 2004 Dec; 28(12):1253-4. PubMed ID: 15475064
[No Abstract] [Full Text] [Related]
19. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
Grey M
Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
[No Abstract] [Full Text] [Related]
20. Anti-glomerular basement membrane disease after alemtuzumab.
Clatworthy MR; Wallin EF; Jayne DR
N Engl J Med; 2008 Aug; 359(7):768-9. PubMed ID: 18703487
[No Abstract] [Full Text] [Related]
[Next] [New Search]
